Influence of Central ₁ Inhibition in Patients with Essential Hypertension

¹ From the Hypertension and Cardiovascular Rehabilitation Unit, Department of Pathophysiology, University of Leuven, Leuven, Belgium

CP-804-S is a substituted phenylbutylamine, known to lower arterial pressure in hypertensive animal models. In a double-blind, crossover study, 12 patients with essential hypertension receiving a constant sodium intake received placebo and CP-804-S, 150 mg daily. Standing (5.5/6.0 mm Hg) and supine (8.5/7.5 mm Hg) blood pressures and standing (7.0 beats/min) and supine (7.5 beats/min) pulse rates were significantly reduced by CP-804-S. Plasma renin activity (0.41 ng/ml/hr) and plasma angiotensin I (47 pg/ml) and angiotensin II (3.0 pg/ml) levels decreased significantly. No significant changes were observed in plasma aldosterone or in the urinary excretion of aldosterone, kallikrein, and prostaglandin E₂, F₂, and F metabolite.